{
  "ticker": "KALV",
  "company_name": "KalVista Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05118958",
      "title": "Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hereditary Angioedema",
      "start_date": "2020-05-19",
      "completion_date": "2020-12-01",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT04349800",
      "title": "A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hereditary Angioedema",
      "start_date": "2018-01-04",
      "completion_date": "2018-09-10",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT04208412",
      "title": "A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hereditary Angioedema",
      "start_date": "2019-07-02",
      "completion_date": "2020-12-08",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT05511922",
      "title": "PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Hereditary Angioedema",
      "start_date": "2022-10-24",
      "completion_date": "2026-06-30",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT05178355",
      "title": "A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hereditary Angioedema",
      "start_date": "2019-02-12",
      "completion_date": "2019-06-21",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT05259917",
      "title": "A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Hereditary Angioedema",
      "start_date": "2022-02-22",
      "completion_date": "2023-12-31",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT06628713",
      "title": "Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat",
      "status": "APPROVED_FOR_MARKETING",
      "phase": "",
      "condition": "Hereditary Angioedema",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT07009262",
      "title": "A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Hereditary Angioedema",
      "start_date": "2025-04-21",
      "completion_date": "2025-11-25",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT06467084",
      "title": "Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Hereditary Angioedema",
      "start_date": "2024-06-24",
      "completion_date": "2026-01-15",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT03466099",
      "title": "Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Diabetic Macular Edema",
      "start_date": "2018-02-16",
      "completion_date": "2019-10-10",
      "enrollment": 0,
      "sponsor": "KalVista Pharmaceuticals, Ltd."
    }
  ],
  "summary": {
    "total_trials": 14,
    "by_phase": {
      "PHASE1": 4,
      "PHASE2": 3,
      "PHASE3": 4,
      "": 3
    },
    "by_status": {
      "COMPLETED": 9,
      "ACTIVE_NOT_RECRUITING": 2,
      "APPROVED_FOR_MARKETING": 1,
      "TERMINATED": 1,
      "AVAILABLE": 1
    },
    "active_trials": 2,
    "completed_trials": 9,
    "conditions": [
      "Angioedema, Hereditary, Types I and II",
      "Diabetic Macular Edema",
      "Hereditary Angioedema"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:22.567953",
    "search_query": "KalVista Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=KalVista+Pharmaceuticals,+Inc."
  }
}